Capricor's DMD therapy lacks efficacy, FDA says ahead of adcomm

AdComNegative

AI Analysis

Summary

The FDA has questioned the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy ahead of an advisory committee meeting. The agency's review team was unable to identify adequate efficacy support for the therapy.

Outcome Details

FDA review team questioned efficacy ahead of advisory committee meeting

Importance:7/10

Sentiment:

-0.70

FDAcell therapyDMDefficacy concernsadvisory committeeDuchenne muscular dystrophy

Read the original article

Published by Endpoints News on July 27, 2026 5:40 PM

Read Original